-
Mashup Score: 1Higher doses of radiotherapy cut treatment time by up to 75 per cent - 7 month(s) ago
People with low to medium-risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Learn how the 2022 Survivor Circle Grants Awardees used the funds to help support their initiatives, providing support to patients in central Texas.
Source: ASTROCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Last year at #ASTRO22, ASTRO had the privilege to provide a $10,000 Survivor Circle Grant to Thrivewell Cancer Foundation & Breast Cancer Resource Center. See how this grant is helping improve patients' lives: https://t.co/MiLH5znTub @ThrivewellSa @BCRCofTexas https://t.co/4zPPwxE6im
-
-
Mashup Score: 02022 ASTRO Annual Meeting OnDemand | ASTRO - 11 month(s) ago
2022 Annual MeetingASTRO’S Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year. The theme for the 2022 ASTRO Annual Meeting is “Artificial Intelligence and Emotional Intelligence: Caring for the Patient in a Wireless World”. The meeting will highlight the potential of AI, Big Data and the latest scientific breakthroughs, in…
Source: academy.astro.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #ASTRO22 Annual Meeting OnDemand will be available until tomorrow, June 1. Access it here: https://t.co/NqM2jHYwwg https://t.co/5gr4gtnbHo
-
-
Mashup Score: 0Genitourinary Cancer Science Highlights | ASTRO - 11 month(s) ago
Course Fees:ASTRO members must log in to the ASTRO website to view and receive the free member rate.Nonmember: $79Member: Free Policies:No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under…
Source: academy.astro.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Science Highlights: Genitourinary Cancer This session highlights six of the most clinically relevant abstracts within the Genitourinary Cancer track of the #ASTRO22 Scientific Program. Access it here: https://t.co/jAvppnboZk https://t.co/8xbtr4g4RC
-
-
Mashup Score: 02022 ASTRO Annual Meeting OnDemand | ASTRO - 11 month(s) ago
2022 Annual MeetingASTRO’S Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year. The theme for the 2022 ASTRO Annual Meeting is “Artificial Intelligence and Emotional Intelligence: Caring for the Patient in a Wireless World”. The meeting will highlight the potential of AI, Big Data and the latest scientific breakthroughs, in…
Source: academy.astro.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #ASTRO22 Annual Meeting OnDemand will be available until June 1. Access it here: https://t.co/NqM2jHYwwg https://t.co/7rMSbff9hp
-
-
Mashup Score: 0Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial L... - 1 year(s) ago
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD By Lisa Kachnic, MD, FASTRO Good afternoon. Today I’m going to discuss the patient reported outcomes from NRG Oncology RTOG 1010 that I was delighted to talk about at our recent ASTRO R…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Lisa Kachnic, MD discussing the Trimodality in addition to Trastuzumab for HER2+ EAC . In this NRG Oncology RTOG 1010 Phase III trial, for treating HER2+ EAC. @lisakachnic1 @ColumbiaMed #RTOG1010 #EAC #ASTRO22 Watch and Share the Video Here: https://t.co/5pb9K9FCJy https://t.co/UaRTcGjeMr
-
-
Mashup Score: 0ASTRO | - 1 year(s) ago
Jump to content Search Open menu Cart Log in Bookmark/Search this post Facebook Twitter LinkedIn Forward My…
Source: academy.astro.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Member Benefit: ASTRO members get FREE access to one of the Science Highlights sessions presented at the #ASTRO22. These sessions highlight key findings in a particular track while featuring cutting-edge research from leaders in the field. Learn more: https://t.co/yMl1dSVVl7 https://t.co/gs8bGt7bUQ
-
-
Mashup Score: 0ASTRO 2022: Human Doctors, Human Patients - 1 year(s) ago
The following is an excerpt from a session at the American Society for Radiation Oncology’s 2022 Annual Meeting, “EI and AI: Caring for the Patient in a Wire…
Source: YouTubeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Open access: #ASTRO22 Presidential Symposium session IV, "EI and AI: Caring for the Patient in a Wireless World." View the session, Human Doctors, Human Patients, here: https://t.co/PypLgxF7VV https://t.co/FmoBJlZlqd
-
-
Mashup Score: 4How AI Is, or Will Soon Be, Relevant in Radiation Oncology - 1 year(s) ago
In his talk, Dr Sanjay Aneja, a professor of radiology at Yale, focused on practical applications of AI that are in the clinic or close to being ready.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
RT @ASTRO_org: #ASTRO22 theme of AI & it’s impact in #radonc in the news by via @medscape: https://t.co/RuHayhd1Sa @SanjayAnejaMD @YaleCanc…
-
-
Mashup Score: 0Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiotherapy - 1 year(s) ago
In epidermal growth factor receptor mutated (EGFR+) metastatic non-small cell lung cancer (mNSCLC), pneumonitis is a known side effect independently associated with both Osimertinib and thoracic radiotherapy (TRT). The objective of this study was to examine the relationship between concurrent Osimertinib and TRT with regards to pneumonitis, and to observe patterns of practice regarding the…
Categories: Hem/Oncs, Latest HeadlinesTweet-
@DrJohnKang @SimonLo21054188 @UCLA @uwradonc @PeterMacRadOnc @RadoncUsc @BeaumontRadOnc @QueensRadOnc @UTDROResidents @IUradonc @StanfordRO_Res @PennRadOnc @EmoryRadOncRes @DouglasEWood1 @JeffBradleyMD @MSK_RadOnc The Canadians also reported data on this topic at #ASTRO22, noting “Osi hold”patterns were variable. 🔥 topic! @DrAlexLouie @cancermd https://t.co/Bfznr1m6Sp
-
🎯 NEWS: Advances in #Radiotherapy mean it’s now possible to treat low to medium-risk, localised #ProstateCancer in just five sessions. Results from the PACE-B trial led by @royalmarsdenNHS and the ICR will be presented at #ASTRO22 on Monday. Read more 👇 https://t.co/kRRiI4i1HZ